In addition, randomized clinical trials have indicated that FGF-2 can effectively enhance the growth of alveolar bone in patients suffering from chronic periodontitis [93], and other studies have demonstrated that the local application of recombinant FGF-2 directly to sites of bone defects using a suitable carrier has been demonstrated to stimulate bone growth [94]. Here, FGF2 is linked to chronic periodontitis.